Abstract
The ubiquitous NF-κB transcription factor has been reported to inhibit apoptosis and to induce drug resistance in cancer cells. Drug resistance is the major reason for cancer therapy failure and neoplastic cells often develop multiple mechanisms of drug resistance during tumor progression. We observed that NF-κB or P-glycoprotein inhibition in the HCT15 colon cancer cells led to increased apoptotic cell death in response to daunomycin treatment. Interestingly, NF-κB inhibition through transfection of a plasmid coding for a mutated IκB-α inhibitor increased daunomycin cell uptake. Indeed, the inhibition of NF-κB reduced mdr1 mRNA and P-glycoprotein expression in HCT15 cells. We identified a consensus NF-κB binding site in the first intron of the human mdr1 gene and demonstrated that NF-κB complexes could bind with this intronic site. Moreover, NF-κB transactivates an mdr1 promoter luciferase construct. Our data thus demonstrate a role for NF-κB in the regulation of the mdr1 gene expression in cancer cells and in drug resistance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- NF-κB:
-
nuclear factor-κB
- IκB:
-
inhibitor of κB
- MDR:
-
multidrug resistance
- P-gp:
-
P-glycoprotein
References
Bargou RC, Emmerich F, Krappmann D, Bomert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C and Dörken B . (1997). J. Clin. Invest. 100, 2961–2969.
Barkett M and Gilmore TD . (1999). Oncogene, 18, 6910–6924.
Beg AA and Baltimore D . (1996). Science, 274, 782–784.
Beg AA, Sha WC, Bronson RT, Ghosh S and Baltimore D . (1995). Nature, 376, 167–170.
Bentires-Alj M, Hellin AC, Ameyar M, Chouaib S, Merville MP and Bours V . (1999). Cancer Res., 59, 811–815.
Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A and Jaffrezou JP . (1998). FASEB J., 12, 101–109.
Biedler JL . (1994). Cancer Res., 54, 666–678.
Bonizzi G, Dejardin E, Piret B, Piette J, Merville M-P and Bours V . (1996). Eur. J. Biochem., 242, 544–549.
Bosch I and Croop J . (1996). Biochim. Biophys. Acta, 1288, F37–F54.
Bours V, Bentires-Alj M, Hellin A, Viatour P, Robe P, Delhalle S, Benoit V and Merville M . (2000). Biochem. Pharmacol., 60, 1085–1089.
Bours V, Burd PR, Brown K, Villalobos J, Park S, Ryseck R-P, Bravo R, Kelly K and Siebenlist U . (1992). Mol. Cell. Biol., 12, 685–695.
Caldenhoven E, Liden J, Wissink S, Van de Stolpe A, Raaijmakers J, Koenderman L, Okret S, Gustafsson J and Van der Saag P . (1995). Mol. Endo., 9, 401–412.
Dejardin E, Bonizzi G, Bellahcéne A, Castronovo V, Merville M-P and Bours V . (1995). Oncogene, 11, 1835–1841.
Gala JL, Noel H, Rodhain J, Ma DF and Ferrant A . (1995). J. Clin. Pathol., 48, 679–681.
Goldie JH (1992). The Chemotherapy Source Book. In: Perry MC (ed). The Chemotherapy Source Book. Williams & Wilkins: Baltimore, pp 54–66.
Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W and Brodeur GM et al. (1989). J. Natl. Cancer Inst., 81, 116–124.
Gros P, Croop J and Housman D . (1986). Cell, 47, 371–380.
Hannun YA . (1994). J. Biol. Chem., 269, 3125–3128.
Hu Z, Jin S and Scotto KW . (2000). J. Biol. Chem., 275, 2979–2985.
Johnstone RW, Cretney E and Smyth MJ . (1999). Blood, 93, 1075–1085.
Karin M . (1999). Oncogene, 18, 6867–6874.
Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A and Green DR . (1998). Mol. Cell, 1, 543–551.
Kolesnick R . (1992). Trends Cell. Biol., 2, 232–236.
Kolesnick R and Golde DW . (1994). Cell, 77, 325–328.
Kuo MT, Liu Z, Wei Y, Lin-Yee YC, Tatebe S, Mills GB and Unate H . (2002). Oncogene, 21, 1945–1954.
Lee JI, Ganster RW, Geller DA, Burckart GJ, Thomson AW and Lu L . (1999). Transplantation, 68, 1255–1263.
Li Q, Van Antwerp D, Mercurio F, Lee KF and Verma IM . (1999). Science, 284, 321–325.
Ling V, Kartner N, Sudo T, Siminovitch L and Riordan JR . (1983). Cancer Treat. Rep., 67, 869–874.
Madden MJ, Morrow CS, Nakagawa M, Goldsmith ME, Fairchild CR and Cowan KH . (1993). J.Biol.Chem., 268, 8290–8297.
Marienfeld R, Neumann M, Chuvpilo S, Escher C, Kneitz B, Avots A, Schimpl A and Serfling E . (1997). Ear. J. Immunol., 27, 1601–1609.
Meyer S, Kohler NG and Joly A . (1997). FEBS Lett., 413, 354–358.
Ogretmen B and Safa AR . (1999). Biochemistry, 38, 2189–2199.
Ogretmen B and Safa AR . (2000). Biochemistry, 39, 194–204.
Ogura M, Takatori T and Tsuruo T . (1992). Nucleic Acids Res., 20, 5811–5817.
Ohga T, Uchiumi T, Makino Y, Koike K, Wada M, Kuwano M and Kohno K . (1998). J. Biol. Chem., 273, 5997–6000.
Pahl HL . (1999). Oncogene, 18, 6853–6866.
Ray A and Prefontaine KE . (1994). Proc. Natl. Acad. Sci. USA, 91, 752–756.
Rayet B and Gelinas C . (1999). Oncogene, 18, 6938–6947.
Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS and Roepe PD . (1997). Biochemistry, 36, 11169–11178.
Ros JE, Schuetz JD, Geuken M, Streetz K, Moshage H, Kuipers F, Manns MP, Jansen PL, Trautwein C and Muller M . (2001). Hepatology, 33, 1425–1431.
Ryan KM, Ernst MK, Rice NR and Vousden KH . (2000). Nature, 404, 892–897.
Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP and Schuetz JD . (2001). J. Biol. Chem., 276, 39359–39367.
Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA and Baldwin ASJ . (1995). Mol. Cell. Biol., 15, 943–953.
Schmidt A, Hennighausen L and Siebenlist U . (1990). J. Virol, 64, 4037–4041.
Smyth MJ, Krasovskis E, Sutton VR and Johnstone RW . (1998). Proc. Natl. Acad. Sci. USA, 95, 7024–7029.
Sonneveld P, Lokhorst HM and Vossebeld P . (1997). Semin. Hematol., 34, 34–39.
Sovak MA, Bellas RE, Kim DW, Zanievski GJ, Rogers AE and Traish AM . (1997). J. Clin. Invest., 100, 2952–2960.
Sundseth R, MacDonald G, Ting J and King AC . (1997). Mol. Pharmacol., 51, 963–971.
Thevenod F, Friedmann JM, Katsen AD and Hauser IA . (2000). J. Biol. Chem., 275, 1887–1896.
Ueda K, Pastan I and Gottesman MM . (1987). J. Biol. Chem., 262, 17 432–17 436.
Um JH, Kang CD, Lee BG, Kim DW, Chung BS and Kim SH . (2001). Oncogene, 20, 6048–6056.
Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM . (1996). Science, 274, 787–789.
Wang C-Y, Mayo MW and Baldwin AS . (1996). Science, 274, 784–787.
Wang CY, Cusack Jr, JC, Liu R and Baldwin Jr, AS . (1999). Nat. Med., 5, 412–417.
Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, Fitzgerald MJ, Rothstein TL, Sherr DH and Sonenshein GE . (1996). EMBO J., 15, 4682–4690.
Zhou G and Kuo MT . (1997). J. Biol. Chem., 272, 15174–15183.
Acknowledgements
MF and NJ are Senior Research Assistants, AC and M-P M are Research Associates at the National Fund for Scientific Research (FNRS, Belgium). M B-A is supported by a Télévie fellowship (FNRS, Belgium). This research was supported by grants from the Centre Anti-Cancereux (Liége, Belgium) and the FRSM (Belgium).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bentires-Alj, M., Barbu, V., Fillet, M. et al. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22, 90–97 (2003). https://doi.org/10.1038/sj.onc.1206056
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206056
Keywords
This article is cited by
-
Involvement and targeted intervention of benzo(a)pyrene-regulated apoptosis related proteome modification and muti-drug resistance in hepatocellular carcinoma
Cell Death & Disease (2023)
-
P38 kinase in gastrointestinal cancers
Cancer Gene Therapy (2023)
-
MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells
Cell Communication and Signaling (2022)
-
Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer
Journal of Nanobiotechnology (2022)
-
PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer
Experimental & Molecular Medicine (2022)